Michael Geffner - 09 Jul 2025 Form 4 Insider Report for Immunovant, Inc. (IMVT)

Role: Chief Medical Officer
Signature: /s/ Christopher Van Tuyl, attorney-in-fact for Michael Geffner
Issuer symbol: IMVT
Transactions as of: 09 Jul 2025
Net transactions value: -$19,998
Form type: 4
Filing time: 11 Jul 2025, 16:15:00 UTC
Previous filing: 25 Apr 2025
Next filing: 25 Jul 2025
SEC: View on sec.gov

Quoteable Key Fact

"Michael Geffner filed Form 4 for Immunovant, Inc. (IMVT) on 11 Jul 2025."

Quick Takeaways

This page summarizes Michael Geffner's Form 4 filing for Immunovant, Inc. (IMVT).
1 reported transaction and 0 derivative rows are listed below.
Filing timestamp: 11 Jul 2025, 16:15.

What Changed

Previous filing in this sequence was filed on 25 Apr 2025.
Current net transaction value: -$19,998.

Why This Matters

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Official SEC Source

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

See Original Filing

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Geffner Michael	Chief Medical Officer	C/O IMMUNOVANT, INC., 320 W 37TH STREET, 6TH FLOOR, NEW YORK	/s/ Christopher Van Tuyl, attorney-in-fact for Michael Geffner	11 Jul 2025	0002007249

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	IMVT	Common Stock	Sale	$19,998	-1,160	-0.51%	$17.24	224,210	09 Jul 2025	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	On April 2, 2024, the holder was granted 54,978 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on April 4, 2024, of which 3,436 of these RSUs vested on July 2, 2025. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
F2	The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.00 - $17.50 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

Content

On April 2, 2024, the holder was granted 54,978 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on April 4, 2024, of which 3,436 of these RSUs vested on July 2, 2025. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.00 - $17.50 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.